Key Drivers
- High cash cushion
- No revenue
- Large cash burn
AIAI Summary
Dyne has moved from speculative R&D optionality to an event‑driven commercial investment hinging on accelerated approval and early launch of z‑rostudirsen (Q2 submission → potential Q1‑2027 launch), so regulatory acceptance, early sales traction, and quarterly burn are now the primary value drivers. Monitor FDA timing/acceptance, DELIVER/HARMONIA/ACHIEVE readouts, early commercialization metrics and burn guidance — any delays or weak uptake would likely force dilutive financing or partnerships and materially reprice the stock.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High cash cushion
- •No revenue
- •Large cash burn
Strong balance sheet (≈$893M cash, low leverage) provides runway, but no revenue and ~−$440M operating loss/−$424M FCF driven by R&D/SG&A create acute cash burn and reliance on financing.
Price Behavior
Key Price Behavior Insights:
- •Above short SMA
- •Firm resistance
- •Elevated volatility
Price is mildly bullish (trading above the last month SMA ~$16.84 at $17.56) but faces firm resistance near $19.78–$19.99 with key support at $14.60–$15.62 and elevated volatility from a sharp reversal and ~35% high-to-low swing.
Sharp reversal from $19.99 on 2026-03-11 to $17.56 on 2026-03-20 and ~35% intra-period range
Sentiment & News
Key News Insights:
- •Phase 3 start
- •Approval timeline
- •Solid cash runway
Dyne advanced key programs—reporting 24‑month DELIVER cardiopulmonary benefit, initiating Phase 3 HARMONIA for z‑basivarsen, and reiterating a Q2 2026 Accelerated Approval timeline for z‑rostudirsen with a potential Q1 2027 launch, backed by ~$1.1B cash into mid‑2028 despite a post‑earnings stock dip.
Progress de‑risks near‑term commercial prospects and should underpin valuation as clinical catalysts unfold, though earnings‑driven volatility may continue
Similar Companies in Healthcare
Other companies in the same sector with AI ratings